

ACI Formulations Limited

**2nd Quarter ended Report 2020-2021
for the six months ended on 31 December 2020**

ACI Formulations Limited

Statement of financial position
Unaudited

Figures in "000"

<i>In Taka</i>	Note	As at 31 December 2020	As at 30 June 2020
Assets			
Property, plant and equipment	5	1,880,622	1,902,608
Right-of-use assets		10,158	12,118
Investments	6	39,765	39,765
Non-current assets		1,930,545	1,954,491
Inventories	8	1,377,424	1,270,805
Trade receivables	9	1,563,252	1,574,240
Other receivables		48,004	40,678
Inter-company receivables	10	8,198	25,404
Advances, deposits and prepayments	11	61,564	79,424
Current tax assets		334,206	323,894
Cash and cash equivalents		201,208	248,676
Current assets		3,593,856	3,563,121
Total assets		5,524,401	5,517,612
Equity			
Share capital		450,000	450,000
Revaluation reserve		1,136,393	1,136,393
Retained earnings		841,652	820,348
Total equity		2,428,045	2,406,741
Liabilities			
Employee benefits	12	51,677	48,492
Deferred tax liabilities		19,493	24,686
Lease liabilities		4,432	4,386
Non-current liabilities		75,602	77,564
Bank overdrafts		29,315	76,793
Loans and borrowings		1,856,037	1,626,971
Lease liabilities- current portion		5,624	6,613
Trade payables		106,516	118,584
Other payables	13	507,199	340,242
Inter-company payables	14	516,063	864,104
Current liabilities		3,020,754	3,033,307
Total liabilities		3,096,356	3,110,871
Total equity and liabilities		5,524,401	5,517,612
Net asset value (NAV) per share		53.96	53.48


Managing Director


Director

Chief Financial Officer


Company Secretary

ACI Formulations Limited


Statement of profit or loss and other comprehensive income
Unaudited

Figures in "000"

<i>In Taka</i>	Note	For the half year ended from		For the 2nd quarter ended from	
		July 2020 to December 2020	July 2019 to December 2019	October 2020 to December 2020	October 2019 to December 2019
Revenue	15	1,913,512	1,655,451	1,067,240	905,382
Cost of sales	16	(1,353,040)	(1,100,073)	(726,179)	(600,035)
Gross profit		560,472	555,378	341,061	305,347
Other income		1,861	2,909	1,003	1,025
Administrative, selling and distribution expenses	17	(329,552)	(362,661)	(176,564)	(183,298)
Operating profit		232,781	195,626	165,500	123,074
Finance costs, net		(71,123)	(119,931)	(31,737)	(57,819)
Profit before contribution to WPPF		161,658	75,695	133,763	65,255
Contribution to WPPF		(8,083)	(3,785)	(6,688)	(3,263)
Profit before tax		153,575	71,910	127,075	61,992
Tax expenses		(42,271)	(19,429)	(34,769)	(16,048)
Profit after tax		111,304	52,481	92,306	45,944
Other comprehensive income		-	-	-	-
Total comprehensive income		111,304	52,481	92,306	45,944
Earnings per share					
Basic earnings per share (BEPS)		2.47	1.17	2.05	1.02




Managing Director



Director



Chief Financial Officer



Company Secretary

ACI Formulations Limited
Statement of changes in equity
Unaudited

Figures in "000"

For the half year ended 31 December 2020				
Attributable to owner of the Company				
<i>In Taka</i>	Share capital	Revaluation reserve	Retained earnings	Total
Balance at 1 July 2020	450,000	1,136,393	820,348	2,406,741
Total comprehensive income				
Profit for the period	-	-	111,304	111,304
Total comprehensive income	-	-	111,304	111,304
Transactions with owners of the company				
Contributions and distributions				
Final dividend for the year 2019-20	-	-	(90,000)	(90,000)
Total transactions with owners of the company	-	-	(90,000)	(90,000)
Balance at 31 December 2020	450,000	1,136,393	841,652	2,428,045

For the half year ended 31 December 2019				
Attributable to owner of the Company				
<i>In Taka</i>	Share capital	Revaluation reserve	Retained earnings	Total
Balance at 1 July 2019	450,000	1,136,393	885,396	2,471,789
Total comprehensive income				
Profit for the period	-	-	52,481	52,481
Total comprehensive income	-	-	52,481	52,481
Transactions with owners of the company				
Contributions and distributions				
Final dividend for the year 2018-19	-	-	(157,500)	(157,500)
Total transactions with owners of the company	-	-	(157,500)	(157,500)
Balance at 31 December 2019	450,000	1,136,393	780,377	2,366,770

ACI Formulations Limited

Statement of cash flows
Unaudited

Figures in "000"

<i>In Taka</i>	Note	For the half year ended from	
		July 2020 to December 2020	July 2019 to December 2019
Cash flows from operating activities			
Cash received from customers and others		1,921,268	1,669,250
Cash paid to suppliers and employees		(1,685,484)	(1,275,015)
Cash (used in)/generated from operating activities		235,784	394,235
Payment for WPPF		(6,609)	(9,553)
Interest paid		(73,714)	(100,030)
Income tax paid		(57,776)	(70,748)
		(138,099)	(180,331)
Net cash (used in)/generated from operating activities*	18	97,685	213,904
Cash flows from investing activities			
Acquisition of property, plant and equipment		(2,719)	(1,984)
Net cash (used in)/generated from investing activities		(2,719)	(1,984)
Cash flows from financing activities			
Inter-company debts received/(paid)		(320,835)	(395,421)
Proceeds from loans and borrowings		229,066	99,079
Payment for lease liability		(3,100)	(3,947)
Dividends paid		(87)	(1)
Net cash (used in)/generated from financing activities		(94,956)	(300,290)
Net increase in cash and cash equivalents		10	(88,370)
Cash and cash equivalents as at 1 July		171,883	168,949
Cash and cash equivalents as at 31 December		171,893	80,579
Closing balance represents			
Cash and cash equivalents		201,208	198,674
Bank overdraft		(29,315)	(118,095)
		171,893	80,579
Net operating cash flow per share (NOCFPS)		2.17	4.75

* See Note 18 for reconciliation of net operating cash flow.


ACI Formulations Limited
Consolidated Statement of Financial Position
Unaudited

Figures in "000"

<i>In Taka</i>	Note	As at 31 December 2020	As at 30 June 2020
Assets			
Property, plant and equipment	5(a)	1,881,815	1,903,985
Right-of-use assets		10,158	12,118
Investments	6(a)	35,817	35,817
Intangible assets	7	5,148	5,148
Non-current assets		1,932,938	1,957,068
Inventories	8(a)	1,377,424	1,270,805
Trade receivables	9(a)	1,564,146	1,575,246
Other receivables		47,841	40,619
Inter-company receivable	10(a)	1,328	17,863
Advances, deposits and prepayments	11(a)	62,260	80,121
Current tax assets		333,998	323,758
Cash and cash equivalents		202,013	249,369
Current assets		3,589,010	3,557,781
Total assets		5,521,948	5,514,849
Equity			
Share capital		450,000	450,000
Revaluation reserve		1,136,393	1,136,393
Retained earnings		837,189	815,586
Equity attributable to the owner of the Company		2,423,582	2,401,979
Non controlling interest		(116)	(122)
Total equity		2,423,467	2,401,857
Liabilities			
Employee benefits	12	51,677	48,492
Deferred tax liabilities		19,401	24,595
Lease liabilities		4,432	4,386
Non-current liabilities		75,510	77,473
Bank overdrafts		29,315	76,794
Loans and borrowings		1,856,037	1,626,971
Lease liabilities- current portion		5,624	6,613
Trade payables		107,896	119,963
Other payables	13(a)	508,036	341,074
Inter-company payables	14	516,063	864,104
Current liabilities		3,022,971	3,035,519
Total liabilities		3,098,481	3,112,992
Total equity and liabilities		5,521,948	5,514,849
Net asset value (NAV) per share	19	53.86	53.38


Managing Director


Director


Chief Financial Officer


Company Secretary

ACI Formulations Limited

Consolidated statement of profit or loss and other comprehensive income
Unaudited

Figures in "000"

<i>In Taka</i>	Note	For the half year ended from		For the 2nd quarter ended from	
		July 2020 to December 2020	July 2019 to December 2019	October 2020 to December 2020	October 2019 to December 2019
Revenue	15(a)	1,914,227	1,656,056	1,067,675	905,693
Cost of sales	16(a)	(1,353,040)	(1,100,074)	(726,179)	(600,036)
Gross profit		561,187	555,982	341,496	305,657
Other income		1,861	2,909	1,003	1,025
Administrative, selling and distribution expenses	17(a)	(329,747)	(362,937)	(176,664)	(183,413)
Operating profit		233,301	195,954	165,835	123,269
Finance costs, net		(71,266)	(119,931)	(31,811)	(57,819)
Profit before contribution to WPPF		162,034	76,023	134,023	65,450
Contribution to WPPF		(8,083)	(3,785)	(6,688)	(3,263)
Profit before tax		153,951	72,238	127,335	62,187
Income tax expenses		(42,342)	(19,489)	(34,825)	(16,079)
Profit after tax		111,609	52,749	92,510	46,108
Other comprehensive income		-	-	-	-
Total comprehensive income		111,609	52,749	92,510	46,108
Total comprehensive income attributable to:					
Owners of the Company		111,603	52,744	92,506	46,105
Non controlling interest		6	5	4	3
		111,609	52,749	92,510	46,108
Earnings per share					
Basic earnings per share (BEPS)	19	2.48	1.17	2.06	1.02


Managing Director


Director


Chief Financial Officer


Company Secretary

ACI Formulations Limited

Consolidated statement of changes in equity
Unaudited

Figures in "000"

For the half year ended 31 December 2020

<i>In Taka</i>	Attributable to owner of the Company				Non-controlling interests	Total equity
	Share capital	Revaluation reserve	Retained earnings	Total		
Balance at 1 July 2020	450,000	1,136,393	815,586	2,401,979	(122)	2,401,857
Total comprehensive income						
Profit for the period	-	-	111,603	111,603	6	111,609
Total comprehensive income	-	-	111,603	111,603	6	111,609
Transactions with owners of the company						
Contributions and distributions						
Final dividend for the year 2019-20	-	-	(90,000)	(90,000)	-	(90,000)
Total transactions with owners of the company	-	-	(90,000)	(90,000)	-	(90,000)
Balance at 31 December 2020	450,000	1,136,393	837,189	2,423,582	(116)	2,423,467

For the half year ended 31 December 2019

<i>In Taka</i>	Attributable to owner of the Company				Non-controlling interests	Total equity
	Share capital	Revaluation reserve	Retained earnings	Total		
Balance at 1 July 2019	450,000	1,136,393	880,352	2,466,745	(127)	2,466,618
Total comprehensive income						
Profit for the period	-	-	52,744	52,744	5	52,749
Total comprehensive income	-	-	52,744	52,744	5	52,749
Transactions with owners of the company						
Contributions and distributions						
Final dividend for the year 2018-19	-	-	(157,500)	(157,500)	-	(157,500)
Total transactions with owners of the company	-	-	(157,500)	(157,500)	-	(157,500)
Balance at 31 December 2019	450,000	1,136,393	775,596	2,361,989	(122)	2,361,867

ACI Formulations Limited
Consolidated statement of cash flows
Unaudited

<i>In Taka</i>	Note	Figures in "000"	
		For the half year ended from	
		July 2020 to December 2020	July 2019 to December 2019
Cash flows from operating activities			
Cash received from customers and others		1,922,095	1,673,355
Cash paid to suppliers and employees		(1,685,488)	(1,278,343)
Cash (used in)/generated from operating activities		236,607	395,012
Payment for WPPF		(6,609)	(9,553)
Interest paid		(73,857)	(100,030)
Income tax paid		(57,776)	(70,815)
		(138,242)	(180,398)
Net cash (used in)/generated from operating activities*	18 (a)	98,365	214,614
Cash flows from investing activities			
Acquisition of property, plant and equipment		(2,719)	(1,984)
Net cash (used in)/generated from investing activities		(2,719)	(1,984)
Cash flows from financing activities			
Inter-company debts received/(paid)		(321,402)	(394,054)
Proceeds from loans and borrowings		229,066	97,242
Payment for lease liability		(3,100)	(3,947)
Dividends paid		(87)	(1)
Net cash (used in)/generated from financing activities		(95,523)	(300,760)
Net increase in cash and cash equivalents		123	(88,130)
Cash and cash equivalents as at 1 July		172,575	169,896
Cash and cash equivalents as at 31 December		172,698	81,766
Closing balance represents			
Cash and cash equivalents		202,013	199,861
Bank overdraft		(29,315)	(118,095)
		172,698	81,766
Net operating cash flow per share (NOCFPS)	19	2.19	4.77

* See Note 18(a) for reconciliation of consolidated net operating cash flow.

ACI Formulations Limited

Notes to the financial statements as at and for the half year ended on 31 December 2020 Unaudited

1 Company profile:

ACI Formulations Limited, a subsidiary of Advanced Chemical Industries Limited, domiciled in Bangladesh. The company's shares are listed with both Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited. The Principal activities of the company are manufacturing and marketing of a number of agrochemical, consumer brand and paint products.

2 Subsidiaries of ACI Formulations Limited:

ACI Formulations Limited has one subsidiary namely Neem Laboratories (Pvt.) Ltd, engaged in manufacturing and marketing of herbal products . ACI Formulations Limited through its voting rights controls the operating and financing activities of this entity.

3 Consolidated Financial statements:

In addition to the separate financial statements, the consolidated financial statements of the company have been prepared and included in this interim financial report as per BFRS 10: Consolidated Financial Statements. In separate Financial Statements, investment in subsidiaries has been carried at cost as per BAS 27: Separate Financial Statements.

4 Selected explanatory notes:

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended 30 June 2020. This interim financial report includes only those selected explanatory notes as were deemed appropriate for better understanding of unaudited financial statements.

		<u>Figures in '000'</u>	
		<u>31- Dec -20</u>	<u>30-June -20</u>
		<u>Taka</u>	<u>Taka</u>
5	Property, plant & equipment		
	Opening balance	2,179,120	2,156,021
	Addition during the period/year	2,482	23,099
		<u>2,181,602</u>	<u>2,179,120</u>
	Accumulated depreciation at the end of period/year	<u>(300,980)</u>	<u>(276,512)</u>
	Closing balance	<u><u>1,880,622</u></u>	<u><u>1,902,608</u></u>
5(a)	Consolidated property, plant & equipment		
	Opening balance	2,184,081	2,160,981
	Addition during the period/year	2,482	23,099
		<u>2,186,563</u>	<u>2,184,080</u>
	Accumulated depreciation at the end of period/year	<u>(304,748)</u>	<u>(280,095)</u>
	Closing balance	<u><u>1,881,815</u></u>	<u><u>1,903,985</u></u>
6	Investments		
	Investment in subsidiaries	3,948	3,948
	Investment in FDR	35,742	35,742
	Investment in shares of ACI Motors Limited	75	75
		<u>39,765</u>	<u>39,765</u>

	<u>31- Dec -20</u>	<u>30-June -20</u>
	<u>Taka</u>	<u>Taka</u>
6(a) Consolidated investments		
Investment in FDR	35,742	35,742
Investment in Shares- ACI Motors Limited	75	75
	<u>35,817</u>	<u>35,817</u>
7 Intangible assets		
Goodwill on acquisition :		
Neem Laboratories (Pvt.) Limited	5,148	5,148
	<u>5,148</u>	<u>5,148</u>
8 Inventories		
Raw and packing materials	639,166	535,479
Work in process	9,098	3,802
Finished goods	604,541	588,585
Goods in transit	138,749	143,045
Other inventories	24,833	25,566
Allowances for slow moving inventory	(38,963)	(25,672)
	<u>1,377,424</u>	<u>1,270,805</u>
8(a) Consolidated inventories		
Raw and packing materials	639,166	535,479
Work in process	9,098	3,802
Finished goods	604,817	588,862
Goods in transit	138,749	143,045
Other inventories	24,833	25,566
Allowances for slow moving inventory	(39,239)	(25,949)
	<u>1,377,424</u>	<u>1,270,805</u>
9 Trade receivables:		
Related parties	-	-
Other than related parties	1,635,045	1,751,275
	<u>1,635,045</u>	<u>1,751,275</u>
Allowances for doubtful debts	(174,800)	(177,034)
	<u>1,460,245</u>	<u>1,574,240</u>
Below six months	1,323,879	1,327,222
Over six months	414,173	424,052
Allowances for doubtful debts	(174,800)	(177,034)
	<u>1,563,252</u>	<u>1,574,240</u>
9(a) Consolidated trade receivables		
Related parties	-	-
Other than related parties	1,738,946	1,752,280
	<u>1,738,946</u>	<u>1,752,280</u>
Allowances for doubtful debts	(174,800)	(177,034)
	<u>1,564,146</u>	<u>1,575,246</u>
Below six months	1,324,773	1,328,228
Over six months	414,173	424,052
Allowances for doubtful debts	(174,800)	(177,034)
	<u>1,564,146</u>	<u>1,575,246</u>

		<u>31- Dec -20</u> <u>Taka</u>	<u>30-June -20</u> <u>Taka</u>
10	Inter-company receivables		
	Neem Laboratories (Pvt.) Ltd.	8,198	25,404
		<u>8,198</u>	<u>25,404</u>
10(a)	Consolidated inter-company receivables		
	ACI Limited	1,328	17,863
		<u>1,328</u>	<u>17,863</u>
11	Advances, deposits & prepayments		
	Advances:		
	Staffs	309	219
	Suppliers & others	38,465	38,489
	VAT current account	7,531	18,776
		<u>46,305</u>	<u>57,484</u>
	Deposits:		
	Security deposits	9,118	12,712
	Bank guarantee margin	4,784	4,784
		<u>13,902</u>	<u>17,496</u>
	Prepayments:		
	Prepaid expenses	1,357	4,444
		<u>1,357</u>	<u>4,444</u>
		<u>61,564</u>	<u>79,424</u>
11(a)	Consolidated advances, deposits & prepayments		
	Advances:		
	Staff	309	219
	Suppliers & others	39,161	39,186
	VAT current account	7,531	18,776
		<u>47,001</u>	<u>58,181</u>
	Deposits:		
	Security deposits	9,118	12,712
	Bank guarantee margin	4,784	4,784
		<u>13,902</u>	<u>17,496</u>
	Prepayments:		
	Prepaid expenses	1,357	4,444
		<u>1,357</u>	<u>4,444</u>
		<u>62,260</u>	<u>80,121</u>
12	Employee benefits		
	Net defined benefit obligation	38,807	36,432
	Other employee benefits	12,870	12,060
		<u>51,677</u>	<u>48,492</u>

	<u>31- Dec -20</u> <u>Taka</u>	<u>30-June -20</u> <u>Taka</u>
13 Other payables		
Creditor for expenses	353,458	273,199
Advance from customer	-	4,199
Interest payable	17,941	20,532
Security money payable	18,401	16,246
Unpaid dividend	102,493	12,580
Withholding tax and VAT payable	6,823	6,877
Workers' profit participation fund	8,083	6,609
	<u>507,199</u>	<u>340,242</u>
13(a) Consolidated other payables		
Creditor for expenses	354,123	273,859
Advance from customer	-	4,199
Interest payable	17,941	20,532
Security money payable	18,401	16,246
Unpaid dividend	102,493	12,580
Withholding tax and VAT payable	6,995	7,049
Provision for workers' profit participation fund	8,083	6,609
	<u>508,036</u>	<u>341,074</u>
14 Inter-company payables		
ACI Limited	516,063	864,104
	<u>516,063</u>	<u>864,104</u>

		for the half year ended from	
		July 2020 to	July 2019 to
		December 2020	December 2019
		<u>Taka</u>	<u>Taka</u>
15	Revenue		
	Crop Care & Public Health	1,528,648	1,283,020
	Mosquito Coil	10,443	5,732
	Aerosol	178,506	135,497
	Paint	130,684	222,218
	Others	65,231	8,984
		<u>1,913,512</u>	<u>1,655,451</u>
15(a)	Consolidated revenue		
	Crop Care & Public Health	1,528,648	1,283,020
	Mosquito Coil	10,443	5,732
	Aerosol	178,506	135,497
	Paint	130,684	222,218
	Others	65,946	9,589
		<u>1,914,227</u>	<u>1,656,056</u>
16	Cost of sales		
	Opening stock	1,127,866	1,547,323
	Purchase	1,384,800	776,341
		<u>2,512,666</u>	<u>2,323,664</u>
	Closing stock	(1,252,805)	(1,315,598)
		<u>1,259,861</u>	<u>1,008,066</u>
	Manufacturing expenses	93,179	92,007
		<u>1,353,040</u>	<u>1,100,073</u>
16(a)	Consolidated cost of sales		
	Opening stock	1,128,142	1,563,768
	Purchase	1,384,800	776,340
		<u>2,512,942</u>	<u>2,340,108</u>
	Stock transferred to ACI Limited	-	(15,498)
	Closing stock	(1,253,081)	(1,315,874)
		<u>1,259,861</u>	<u>1,008,736</u>
	Manufacturing expenses	93,179	91,338
		<u>1,353,040</u>	<u>1,100,074</u>
17	Administrative, selling and distribution expenses		
	Administrative expenses	70,291	64,581
	Distribution expenses	57,976	55,331
	Selling expenses	201,285	242,749
		<u>329,552</u>	<u>362,661</u>
17(a)	Consolidated administrative, selling and distribution expenses		
	Administrative expenses	70,486	64,857
	Distribution expenses	57,976	55,331
	Selling expenses	201,285	242,749
		<u>329,747</u>	<u>362,937</u>

18 Reconciliation of net operating cash flow

<i>In Taka</i>	for the half year ended from	
	July 2020 to December 2020	July 2019 to December 2019
Profit after tax	111,304	52,481
Adjustment for non cash items and others:		
- Depreciation and amortization	24,705	32,042
- Provisions	1,956	12,816
- Net finance cost	(2,591)	19,903
- Tax expense	(15,505)	(51,319)
- Contribution to WPPF	1,474	(5,769)
Changes in:		
- Inventories	(119,910)	158,306
- Trade and other receivables	5,896	1,166
- Advances, deposit and prepayments	17,862	(27,982)
- Trade and other payables, employment benefits'	72,494	22,260
Cash generating from operating activities	97,685	213,904

18 (a)

Reconciliation of consolidated net operating cash flow

<i>In Taka</i>	for the half year ended from	
	July 2020 to December 2020	July 2019 to December 2019
Profit after tax	111,609	52,749
Adjustment for:		
- Depreciation and amortization	24,797	32,227
- Bad debts and inventory loss/(recovery)	1,956	12,816
- Net finance cost	(2,591)	19,903
- Tax expense	(15,433)	(51,326)
- Contribution to WPPF	1,474	(5,769)
Changes in:		
- Inventories	(119,910)	160,149
- Trade and other receivables	6,112	3,778
- Advances, deposit and prepayments	17,862	(27,038)
- Trade and other payables, employment benefits'	72,489	17,125
Cash generating from operating activities	98,365	214,614

	for the half year ended from	
	July 2020 to December 2020	July 2019 to December 2019
19 Consolidated EPS, NAV per Share and NOCFPS:		
Weighted average number of ordinary shares (in thousand)	45,000	45,000
Consolidated profit attributable to equity holders of the Company (Taka '000)	111,603	52,744
Earnings per share (Taka)	2.48	1.17
Consolidated net asset attributable to equity holders of the Net asset value (NAV) per share	2,423,582 53.86	2,401,979 53.38
Consolidated cash flows from operating activities (Taka '000)	98,365	214,614
Net operating cash flows per share (NOCFPS)	2.19	4.77

The consolidated revenue grew by around 16% over SPLY propelled by higher sales mainly in CC&PH business. Moreover, effective control over operating expenses coupled with lower financing cost led to higher consolidated profit after tax against SPLY resulting in higher consolidated EPS and NAV per share. On the other hand, consolidated NOCFPS decreased mainly due to inventory build-up for upcoming 3rd quarter .

20 Segment reporting

The Company has four reportable segments, as described below, which are the Company's strategic divisions. The strategic divisions offer different products and services, and are managed separately because they require different technology and marketing strategies. For each of the strategic divisions, the Company's CEO reviews internal management reports at least on a quarterly basis. The following summary describes the operations in each of the Company's reportable segments:

Crop Care and Public Health (CC & PH) To manufacture and sell crop care and public health products.

Mosquito Coil (M Coil) To manufacture and sell mosquito coil products

Aerosol To manufacture and sell aerosol and air freshener products.

Paint To manufacture and sell of paint products.

Figures in '000'

Particulars	CC & PH		M Coil		Aerosol		Paint		Unallocated		Total	
	for the half year ended on		for the half year ended on		for the half year ended		for the half year ended		for the half year ended on		for the half year ended on	
	31-Dec-20	31-Dec-19	31-Dec-20	31-Dec-19	31-Dec-20	31-Dec-19	31-Dec-20	31-Dec-19	31-Dec-20	31-Dec-19	31-Dec-20	31-Dec-19
	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka
Segment revenue:												
External revenues	1,528,648	1,283,020	10,443	5,732	178,506	135,497	130,684	222,218	16,917	8,984	1,865,198	1,655,451
Inter-segment revenues	-	-	-	-	-	-	-	-	49,029	605	49,029	605
Total revenue	1,528,648	1,283,020	10,443	5,732	178,506	135,497	130,684	222,218	65,946	9,589	1,914,227	1,656,056
Financing costs	(61,562)	(99,362)	-	-	-	-	(8,966)	(19,601)	(738)	(969)	(71,266)	(119,932)
Depreciation	(10,382)	(16,733)	(8,941)	(10,053)	(2,494)	(2,944)	(2,489)	(2,572)	(584)	(622)	(24,890)	(32,924)
Cost of sales excluding depreciation	(980,655)	(807,124)	(24,202)	5,031	(165,579)	(99,791)	(102,455)	(168,563)	(62,769)	(5,957)	(1,335,660)	(1,076,404)
Operating expenses excluding depreciation	(257,504)	(277,641)	(3,252)	(4,592)	(3,965)	(4,985)	(57,466)	(66,373)	(49)	(91)	(322,236)	(353,682)
Other income /(expense)	1,371	2,134	-	-	19	258	471	517	-	-	1,861	2,909
Profit before tax	208,920	80,079	(24,654)	(3,688)	6,163	26,633	(38,210)	(32,655)	1,733	1,870	153,951	72,238
Reportable segment assets	2,821,940	2,802,759	697,341	708,443	729,601	685,821	433,918	441,225	839,148	876,601	5,521,948	5,514,849
Reportable segment liabilities	1,740,179	1,966,169	7,713	6,885	141,202	124,742	106,280	99,360	1,103,107	915,836	3,098,481	3,112,992

21 Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.